Healthcare >> CEO Interviews >> October 17, 2003
DANIEL D. BURGESS became Chief Operating Officer and Chief Financial
Officer of Hollis-Eden Pharmaceuticals, Inc., in August 1999. Mr.
Burgess joined Hollis-Eden from Nanogen Inc., where he served as Vice
President and Chief Financial Officer. Prior to joining Nanogen, Mr.
Burgess spent 10 years with Gensia Sicor, Inc. (now Sicor, Inc.) and
Gensia Automedics, Inc., a partially owned subsidiary of Gensia Sicor.
He served as President and a Director of Gensia Automedics, where he was
responsible for all functional areas of this medical products company.
In addition, he was Vice President and Chief Financial Officer of Gensia
Sicor, where he was responsible for finance, investor relations,
business development and other administrative functions. During his
tenure with Gensia, Mr. Burgess helped transform the company from a
research stage company with less than 50 employees into a fully
integrated specialty pharmaceutical company with more than $150 million
in annual revenues. Mr. Burgess was instrumental in helping Gensia raise
over $400 million in various public and private financings and was a key
figure in a number of acquisitions and in-licensing and out-licensing
transactions. Prior to joining Gensia, Mr. Burgess held positions at
Castle & Cooke, Inc., and Smith Barney, Harris Upham and Company. He
received a degree in economics from Stanford University and an MBA from
Harvard Business School. Profile
products?
Mr. Burgess: Hollis-Eden has developed a class of hormones known as
immune regulating hormones. These are
